
==== Front
Int J Biol Sci
Int J Biol Sci
ijbs
International Journal of Biological Sciences
1449-2288
Ivyspring International Publisher Sydney

10.7150/ijbs.98806
ijbsv20p4872
Review
Elucidating the evolving role of cuproptosis in breast cancer progression
Zhu Zhanyong 1#
Zhu Keyu 2#
Zhang Jun 3#
Zhou Yunhua 4✉
Zhang Qi 25✉
1 Department of Plastic Surgery, Renmin Hospital of Wuhan University, No. 238 Jiefang Road, Wuhan, 430060, Hubei Province, China.
2 Department of Plastic and Cosmetic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China.
3 Department of Thyroid and Breast Surgery, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen, 518067, China.
4 Department of Wound Repair Surgery, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430062, Hubei Province, China.
5 Xianning Medical College, Hubei University of Science & Technology, Xianning, 437000, Hubei, China.
✉ Corresponding authors: Yunhua Zhou, Ph.D., Department of Wound Repair Surgery, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430062, Hubei Province, China. E-mail address: 2042256954@qq.com. Qi Zhang, Ph.D., Department of Plastic and Cosmetic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, Hubei, China. E-mail address: zhangqi06172@tjh.tjmu.edu.cn.
# Co-first author.

Competing Interests: The authors have declared that no competing interest exists.

2024
9 9 2024
20 12 48724887
23 5 2024
20 8 2024
© The author(s)
2024
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See https://ivyspring.com/terms for full terms and conditions.
Breast cancer (BC) persists as a highly prevalent malignancy in females, characterized by diverse molecular signatures and necessitating personalized therapeutic approaches. The equilibrium of copper within the organism is meticulously maintained through regulated absorption, distribution, and elimination, underpinning not only cellular equilibrium but also various essential biological functions. The process of cuproptosis is initiated by copper's interaction with lipoylases within the tricarboxylic acid (TCA) cycle, which triggers the conglomeration of lipoylated proteins and diminishes the integrity of Fe-S clusters, culminating in cell demise through proteotoxic stress. In BC, aberrations in cuproptosis are prominent and represent a crucial molecular incident that contributes to the disease progression. It influences BC cell metabolism and affects critical traits such as proliferation, invasiveness, and resistance to chemotherapy. Therapeutic strategies that target cuproptosis have shown promising antitumor efficacy. Moreover, a plethora of cuproptosis-centric genes, including cuproptosis-related genes (CRGs), CRG-associated non-coding RNAs (ncRNAs), and cuproptosis-associated regulators, have been identified, offering potential for the development of risk assessment models or diagnostic signatures. In this review, we provide a comprehensive exposition of the fundamental principles of cuproptosis, its influence on the malignant phenotypes of BC, the prognostic implications of cuproptosis-based markers, and the substantial prospects of exploiting cuproptosis for BC therapy, thereby laying a theoretical foundation for targeted interventions in this domain.

breast cancer
cuproptosis
copper
cuproptosis-related genes
diagnosis
therapy
==== Body
pmcIntroduction

Breast cancer (BC) remains the most prevalent and high-mortality type of female tumor worldwide, imposing a heavy social burden 1. With the intensive development of diagnostic and therapeutic technologies, individualized treatment strategies based on molecular typing have led to a significant improvement in the prognosis of BC patients 2,3. However, the prognosis of some high-risk BC types or advanced BC is still poor 4. The genetics, pathology, and molecular biology of patients are profoundly altered, and continued exploration will bring about profound transformations in the management of BC 5.

Cell death, as one of the metabolic processes, is of importance for the maintenance of biological life, along with cell proliferation and differentiation 6,7. Different programmed cell deaths (PCDs) are extensively involved in tumor evolution, including apoptosis, necroptosis, pyroptosis, ferroptosis, and cuproptosis 8. PCDs are cellular suicide mechanisms that have arisen in living organisms during a long evolutionary process and are closely related to a variety of pathophysiological phenomena, including cell fate, immune regulation, tumors and infectious diseases, among others 9. Notably, PCD involves specific intracellular gene regulatory molecular programs, and many neoplastic diseases are associated with defects in one or several of the PCD processes 10. In particular, copper homeostasis in the body is sustained by modulating copper absorption, transport, and excretion 11. Copper homeostasis is fundamental to cellular homeostasis since the accumulation of intracellular copper induces oxidative stress and disrupts many cellular functions 12.

Cuproptosis begins with the binding of copper to lipolysis in the tricarboxylic acid (TCA) cycle, contributing to consequential protein aggregation, proteotoxic stress, and eventually cell death 13. Cuproptosis is dysregulated in BC tissues, and cancer cells have a higher copper requirement compared to undivided cells. High heterogeneity in the expression variation of cuproptosis-related genes (CRGs) in BC reveals that the imbalance of CRG expression plays a pivotal role in BC development. Abnormal copper accumulation promotes the malignant transformation of cells 14. CRGs and BC progression are inextricably linked 15. For example, ATP7B and dihydrolipoamide S-acetyltransferase (DLAT) protein expression showed a high expression pattern in BC samples and had an impact on the tumor cell cycle. The novel constructed risk signatures of CRGs have predictive properties for the prognosis, tumor microenvironment (TME), and immunotherapy of BR patients 16. Some CRGs, DLAT, solute carrier family 31 member 1 (SLC31A1), ATP7A, and ATP7B, are distinctively associated with overall survival (OS) in BC patients 17. Zou et al. established a 12-gene cell death index (CDI), and patients in the triple negative breast cancer (TNBC) cohort with a high index had worse prognostic outcomes 18. The CDI score correlated with ICs and sensitivity to standard adjuvant chemotherapy and palbociclib.

Given the importance of cuproptosis and its involvement in multiple aspects of BC, we systematically review in this article the basic concepts of cuproptosis, the impact of cuproptosis on the malignant biological behaviors of BC, the prognostic value of cuproptosis based on cuproptosis, as well as the huge potential of cuproptosis for BC treatment. An in-depth understanding of cuproptosis and its underlying molecular mechanisms is beneficial for appreciating the evolution of BC and screening cuproptosis-targeted therapeutic strategies.

Copper metabolism and cuproptosis in vivo

Copper, an essential trace element in the animal body, is primarily found in muscle, bone, and liver 19. Owing to its redox properties, copper can serve as a cofactor for key enzymes involved in a variety of biological processes, including energy conversion, antioxidant, intracellular oxidative metabolism, and epigenetic modifications 20.

The main source of copper in the body is absorbed from food through the duodenum and small intestine 21. The six-transmembrane epithelial antigen of the prostate (STEAP) can reduce Cu2+ from food to Cu+, which then enters the cells through the mediation of copper transport protein 1 (CTR1) 22. Cu2+ can also be transported into the cells via divalent metal transporter 1 (DMT1), but it cannot be utilized directly 23. After being absorbed by the epithelial cells, Cu can be transported to the other side of the epithelium via the copper molecular chaperone antioxidant 1 (ATOX1), then secreted into the bloodstream through the ATPase copper transporting alpha (ATP7A) 24. Soluble carriers in the blood that bind to copper ions, such as albumin, copper-green proteins, and histidine, can bind to copper and then transport it to the liver, which is the primary organ for storing and excreting copper 25,26. Copper storage proteins, such as metallothionein and glutathione, can mediate Cu storage by chelating with Cu+, and excess Cu is secreted into the bile, mainly through the ATPase copper transporting beta (ATP7B) on hepatocytes, and then gets excreted out of the body 27,28.

Collectively, these processes mediate copper homeostasis at the macroscopic level in vivo. At the cellular level, copper enzymes, copper molecular chaperones, and membrane transport proteins, synergistically regulate the uptake, efflux, and utilization of copper, thus maintaining copper homeostasis 29,30. Copper transporter 1 (CTR1) and STEAP are cooperatively responsible for transporting copper into the cells, while copper molecular chaperones, such as CCS, Atox 1, and Cox17, are in charge of intracellular copper transport 31,32. CCS delivers copper to superoxide dismutase 1 (SOD1), which is involved in reactive oxygen species (ROS) scavenging and maintenance of copper homeostasis 33. ATOX1 binds Cu+ and transfers it to ATP7A and ATP7B in the trans-Golgi network, enhancing the synthesis of cuproenzymes 34. When intracellular copper levels are overly high, ATP7A and ATP7B can facilitate the efflux of excess copper through translocation to the cell membrane 35. Cox17 can target Cu+ to the mitochondrial membrane gap and insert it into cytochrome oxidase C (CCO) via COX11 or SCO1, participating in cellular metabolism 36,37. Abnormalities in these processes lead to disturbed copper metabolism and disrupted copper homeostasis.

Maintaining normal copper homeostasis is necessary for normal life activities. Lack of copper ions may lead to deficiencies in the activity of multiple enzymes and the development of disease 38. However, excessive copper accumulation can also harm cells. Copper ions undergo redox reactions accompanied by electron transfer and ROS production, capable of damaging a variety of cellular biomolecules 39,40. Elevated copper levels are also linked with the severity and progression of several cancers. Copper can promote tumorigenesis and progression by enhancing cell proliferation, inducing drug resistance in tumor cells, stimulating angiogenesis, and promoting tumor cell migration 41,42. On the other hand, the application of copper alone or together with ion carriers can induce cancer cell death, such as cuproptosis 43,44.

Cuproptosis is a regulatory cell death pattern distinct from other oxidative stress-related cell death patterns 45. The morphological features of cuproptosis are similar to those of apoptosis, characterized by mitochondrial crumpling, cell membrane rupture, endoplasmic reticulum damage, and chromosome breaks 46. In this process, Cu+ directly binds to lipoylated mitochondrial protein fractions of the tricarboxylic acid (TCA) cycle and acts on Fe-S clusters, inducing the aggregation of lipoylated proteins and the reduction of Fe-S clusters, ultimately resulting in cellular death mediated by proteotoxic stress 47 (Figure 1). Some critical components play important roles in this process. For example, as a key gene in cuproptosis, FDX 1 is involved in proteolipid acylation and reduction of Cu2+, but its exact mechanism still requires further interpretation. Several other CRGs, including those encoding LIPT 1, LIAS, DLD, DLAT, PDHA 1, and PDHB, are also significantly involved in this procedure.

The roles and mechanisms of cuproptosis in remodelling BC progression

As an oncogene, cyclin-dependent kinase inhibitor 2A (CDKN2A) can encode p16 and p14, often expressed as homozygous deletions in a variety of cancers, such as oral squamous cell carcinoma and melanoma 48,49. Deletions, point mutations, promoter hypermethylation, and transcriptional abnormalities of the CDKN2A gene, are responsible for the inactivation of the CDKN2A gene, resulting in cell cycle dysregulation. CDKN2A is identified as a key CRG whose high expression was predictive of poor outcomes through model screening constructed by artificial intelligence 50. Knockdown of CDKN2A using siRNA technology resulted in a significant decrease in Zeb1, vimentin, and MMP9, indicators related to BC cell migration and metastasis, as well as down-regulation of the expression of MEGEA4, phosphorylated STAT3, PD-L1, and caspase-3. Hence, CDKN2A/MAGEA4 was a pathway that was critically associated with BC chemosensitivity, invasion, and metastasis. In another similar bioinformatic study, CDKN2A was also recognized as a pivotal modulator influencing TNBC course by driving ferroptosis and cuproptosis 51. Histochemical results of multiple samples showed that c-Myc was strongly associated with BC stemness and significantly correlated with cuproptosis-induced cell death 52. Cuproptosis is an underlying downstream of c-Myc-mediated malignant changes in tumors. DLAT fulfils a similar role in BC. Sha et al. found that high level of DLAT was associated with resistance to HER2-targeted therapy, and BC sensitivity to trastuzumab was enhanced after knocking down DLAT 53. Dihydrolipoyl dehydrogenase (DLD) is another critical CRG, but its role in BC prognosis remains unclear. Xu et al. investigated the potential impact of DLD on BC progression 54. Knockdown of DLD in BC cell lines MDA-MB-468 and SK-BR-3, significantly inhibited cell migration, invasion, and proliferation. High DLD expression in tumor regions was associated with PD-L1 and macrophages, while stromal regions showed an increase in CD4+ T cells and macrophages.

Alternatively, some metabolites may affect the progression of BC by interfacing with CRGs. For example, butyrate, a common short-chain fatty acid (SCFA), has been shown to regulate the development of BC, though its underlying mechanisms were previously unclear. Zhang et al. found that SCFA levels were lower in fecal samples from BC patients compared to controls 55. Butyrate significantly inhibited the viability, migration, and invasion of T47D cells in a dose-dependent manner and effectively suppressed tumor growth in animal models. Mechanistically, butyrate inhibited the expression of Toll-like receptor 4 (TLR4), and promoted the expression of CRGs PDXK and SLC25A28. Overexpression of TLR4 reversed the effects of butyrate on PDXK and SLC25A28 expression and on the malignant behavior of T47D cells. These findings suggest that CRGs are important potential prognostic markers in BC, offering new therapeutic targets and avenues for BC treatment.

CeRNA is a complex regulatory network between ncRNAs and coding RNAs in the cell via miRNAs 56,57. The core principle of ceRNA network is to form a competitive relationship between mRNAs, lncRNAs, circRNAs, through the competitive binding mechanism of miRNAs 58,59. This interaction of multiple makes the intracellular regulatory network more flexible and helpful in adapting to different biological environments 60. By using bioinformatic analysis of multiple databases, Lian et al. revealed that SLC31A1 was abundantly expressed in BC tissues and cell lines and was intimately connected to both recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) 61. Functionally, SLC31A1, which was involved in copper ion transport, was found to be associated with m6A-related genes, especially YTHDF3. In-depth, the up-regulation of SLC31A1 expression mediated by the LINC00511-miR-29-3p axis was implicated in the modulation of copper ion transport and poor prognosis of BC, and was positively linked to the tumor immune cell infiltration, immune markers, and cancer-associated fibroblasts (CAFs) 61. Similarly, lncRNA XIST was also found to regulate the miR-92b-3p/MTF1 axis for shaping BC progression, deserving further exploration by in vitro and in vivo assays 62. In another multi-method bioinformatic study, LINC01614 likewise facilitated the expression of SLC31A1 by inhibiting miR-204-5p and was involved in BC progression. Thus, LINC01614/miR-204-5p/SLC31A1 is also a regulatory chain related to cuproptosis and was critical for BC 63. In addition, PRNP was identified as a core CRG involved in tumor progression in BC. hsa-miR-192-5p and hsa-miR-215-5p were confirmed to target regulatory PRNP by PPI and immunoassay, and a ceRNA regulatory network was identified, including mRNAPRNP/miRNA hsa-miR-215-5p and hsa-miR-192-5p/lncRNA CARMN axis 64. Zhang et al. constructed a risk model for Estrogen receptor-positive (ER+) BC consisting of 4 CRGs, including DLD, DBT, DLAT, and ATP7A, that predicted immune infiltration, immune function, ICs, characteristic gene changes, and pathway activation in different scoring risk subgroups 65. In this system, the authors identified two ceRNA action networks lnc RNA C6orf99/hsa-miR-370-3p and hsa-miR-432-5p/DLD, and that DLD was a core target associated with resistance to ET through cuproptosis (Figure 2).

Cuproptosis-related applications in BC diagnosis

Mammography imaging and magnetic resonance imaging, histopathologic testing, and serologic screening methods, have been common clinical screening tools for BC in the present 66,67. Several novel techniques, including the applications of microwave imaging and artificial intelligence, offer new possibilities for the early diagnosis and treatment of BC 68,69. However, postoperative failure, metastasis, relapse, and chemoresistance, are the primary factors contributing to therapeutic failure in BC patients, especially TNBC. Currently, desirable predictive models for these factors are still lacking 17,70,71. Cuproptosis regulates a wide range of biological functions and possesses a contributory function in shaping the complexity and diversity of the TME, then its associated hallmarks are potentially the basic unit of BC prediction 72,73. Models based on multiple CRGs and signatures are capable of responding to a variety of clinical prognostic evaluations, tumor mutation burden (TMB), immune cell infiltration and activity, immune checkpoint, and chemotherapeutic drug sensitivity 74-76. Here, we divide this section into single CRG-based, multiple CRGs, and combined CRG-related genes.

Models based on single CRG

SLC31A1 is a critically endorsed class of copper transporters that impacts copper uptake at the cell membrane by functioning as a homotrimer, and its overexpression promotes greater copper uptake 77. As an influential player in the cuproptosis gene family, SLC31A1 has been confirmed to be highly correlated with poor prognosis in a range of tumor types, including BC, cervical cancers, head and neck squamous cell carcinoma, and esophageal carcinoma (ESCA) 63,78. Li et al. integrated SLC31A1 with other clinical parameters, such as age, T-stage, N-stage, and clinical staging to construct a predictive model, demonstrating favorable predictive effectiveness for both near-term and long-term OS 17. High expression of SLC31A1 was statistically associated with immunity, metabolic dysregulation, and treatment responsiveness to paclitaxel and CTLA4.

Pyruvate dehydrogenase E1 component subunit alpha (PDHA1) is a key gene involved in cuproptosis and consequently in the glucose metabolism reprogram of cancer cells 79. PDHA1 is implicated in a variety of signaling pathways in the malignant evolution of tumors, including DNA damage, cell invasion, immunosuppression, and angiogenesis 80. PDHA1 is potentially a prognostic and immune-related parameter for multiple cancers. For example, Huang et al. demonstrated through multiple validation and characterization that PDHA1 was a regulator of BC malignant progression and that PDHA1 expression was tightly correlated with the infiltration of a variety of immune cells, including CD4+ T cells, macrophage subsets, and mast cells 81. Thus, this study demonstrated that PDHA1 was an independent factor in BC prediction and was expected to be a novel immunotherapeutic target.

Models based on multiple CRGs

Models based on multiple differentially expressed CRGs are able to capture more BC patient information than a single CRG and may be more efficient in terms of accuracy 82,83. After discovering the pivotal role of DLAT in BC, Sha et al. constructed a risk score model for HER 2+ BC patients based on CRGs, and confirmed DLAT as an independent prognostic factor for HER2+ BC patients in further analysis 53. Xia et al. matched 21 known CRGs with differentially expressed ncRNAs in BC, subsequently screening them with machine learning algorithm 84. They ultimately chose five key CRGs from these to construct a diagnostic model together, which was able to predict the molecular subtypes of BC accurately, providing a new perspective on personalized treatment for BC patients. Zhu et al. constructed 6 CRGs-comprising risk signatures for BC prediction 85. The model demonstrated excellent capabilities to delineate high-risk and low-risk groups, to evaluate higher than TNM staging, and to assess immune responsiveness. Zheng et al. reported a signature based on CRGs, and emphasized that patients in the high-risk group classified according to the model had lower OS, and there were significant differences between the high- and low-risk groups in terms of OS, immune status, and sensitivity to chemotherapy 86. Jiang et al. successfully built a risk model based on 6 CRGs, comprising DKN2A, MTF1, PDHA1, DLD, LIPT1, and FDX1. The model line was predictive of pre-pTNM, MSI, drug sensitivity, and immune infiltration characteristics in BC patients 62.

ER+ BC is the most common subtype of BC and is accompanied by features such as immune stress and epigenetic modifications 87. The treatment of ER+ BC consists of interventions that inhibit estrogen secretion and/or directly target the ER, improving patient outcomes 88. However, the resistance and immune profile of such therapies require clearer predictive modalities and indications. Fan et al. constructed a risk scoring system by using CRGs for ER+ early BC, showing that High expression of FDX1, LIAS, LIPT1, DLD, PDHB, and ATP7B and low expression of CDKN2A were related to better RFS 89. This model specified a higher risk of recurrence with a high CRG score and therefore could be used synergistically as a complement to conventional clinical parameters for long-term prognostic evaluation of ER+ early BC.

Models based on combined CRG-related genes

Models constructed based on multiple composite genes are also common approaches nowadays, including those based on PCD-associated ncRNAs, PCD-associated mRNAs, or Mendelian randomization 90,91. In BC, cuproptosis-related lncRNAs (CRLs) are the most common type of ncRNAs used to construct BC prediction models. In contrast, cuproptosis-related miRNAs and circRNAs based on cuproptosis have barely been mentioned.

CRLs are instrumental in mediating the biological functions of BC with the potential to predict BC prognosis and sensitivity to various therapies 92. The resistance biomarker expressions of CDK4/6 (CCNE1, E2F1, and E2F2) and PARP (BRCA1/BRCA2) were lower in low-risk patients, suggesting that low-risk patients were more prone to the application of these two inhibitors. Utilizing the TCGA database in combination with machine learning, Li et al. constructed a cuproptosis-associated lncRNA-based prediction model, which exhibited excellent performance in predicting the prognosis, tumor mutation burden, and responsiveness to immunotherapy in BC patients 93. Similarly, Sun et al. also screened differentially expressed cuproptosis-associated lncRNAs in BC samples 94. Cellular experiments confirmed that AC104211.1 and LINC01863 influenced BC cell proliferation, while the screened drugs, Trametinib, 5-fluorouracil, and AICAR significantly inhibited the viability of MCF-7 cells. Xu et al. found the cuproptosis genes FDX1, PDHA1, and DLAT were remarkably down-regulated in BC tissues, furthermore, they identified a unique model BCCuS based on cuproptosis-related 2-lncRNAs USP2-AS1 and NIFK-AS1 for BC prediction 95. The BCCuS model had high prognostic predictive performance and was strongly associated with high TMB and immune assessment.

Li et al. also constructed a characteristic predictive model using 5 CRLs, C2orf91 (LINC02898), PRKAR1B-AS1, AC012213.3, AL137847.1, MFF-DT, and the pathways of these CRLs were closely related to immune responsiveness 96. The model was able to respond well to the high sensitivity of multiple drugs to high risk, including Lapatinib, Sunitinib, Phenformin, and Idelalisib. Li et al. used 10 CRLs for constructing a risk signature for BC risk stratification, which obtained desirable predictive capabilities 97. Yu et al. constructed a risk model based on 11 CRLs, demonstrating satisfactory prognostic prediction performance in BC 98. Besides, this model was also related to the assessment of immune checkpoint inhibitors (ICIs), TMB, m6A, and agent sensitization. Guo et al. reported a cuproptosis-associated risk model with 9 CRLs as an effective tool for independent prognostic prediction of BC 99. Moreover, the model also possessed immuno-predictive efficacy, and the low-risk group was able to respond better to immunotherapy, showing higher CD8+ T-cell infiltration and activation, and more TMB. Jiang et al. reported a novel signature based on 11 CRLs, and this signature could independently predict the prognosis and TMB 100. Furthermore, the high score cataloged by this signature showed high drug sensitivity for anti-CD276 therapy and imatinib, lapatinib, and pazopanib. Pan et al. also mined a model constructed from 10 CRLs and had similar predictive functions as independent prognostic predictors for BC 101. Zhang et al. adopted cuproptosis-related ferroptosis-related genes to investigate their expression patterns in predicting OS of BC. This study posed the capability of the pattern, and its relationship with steroid biosynthesis, ABC transporters, and drug sensitivity of AKT inhibitor VIII and cisplatin 102.

There is probably a robust link between cuproptosis and tumour immunity. Wang et al. explored the intricate relationship between cuproptosis and tumor immunity in TNBC to establish prognostic models based on miRNA and mRNA 103. By comparing the expression levels of CRGs between normal individuals and the TCGA-TNBC cohort, they identified 5 prognostic miRNAs (miR-203a-3p, miR-1277-3p, miR-135b-5p, miR-200c-3p, and miR-592) and 3 biomarkers (DENND5B, IGF1R, and MEF2C) that were significantly associated with TNBC prognosis. These factors might influence TNBC progression by affecting adipogenesis, inflammatory response, hormone metabolism, and the immune microenvironment. The cancer immunity cycle (CIC) is a crucial component of the cancer immune microenvironment, and might interact with cuproptosis to exert biological functions. Liu et al. utilized the TIP database and machine learning to identify 4 key cuproptosis-CIC interactions in BC and constructed a prognostic prediction model 104. Further experiments confirmed that HSPA9 was a critical protein that restricted BC growth and migration. These studies provide insights into the complex relationship between the cuproptosis-CIC network and the BC immune microenvironment (Table 1).

Cuproptosis-targeted therapy in BC

Evidence suggests that tumor cells undergoing regulatory death can remodel TME immunogenicity and intensity of immune effects, demonstrating the potential to inhibit cancer metastasis and recurrence 105. Other stromal and immune-type cells and components in the TME also undergo a definite degree of PCD effects, all of which exert a certain positive regulatory effect on tumor immunity 106,107. Currently, therapeutic modalities utilizing cuproptosis-targeted induced copper ion carriers in combination with small molecule drugs have demonstrated some tumor therapeutic potential 108.

Some TNBC-related CRGs, including ATP7A, PIK3CA, LIAS, and LIPT, were closely associated with some mutations and immune infiltration 71. Moreover, several drugs targeting cuproptosis were screened for the treatment of TNBC, including dasatinib in combination with ABT-737, Erastin or methotrexate, docetaxel/isprinib combination. Zinc pyrithione (ZnPT), an antifungal drug for seborrheic dermatitis, contributes to DNA damage and PARP-dependent energetic crisis 109. ZnPT is capable of exerting certain anticancer effects, including inhibition of PDAC tumor progression through suppression of SDCBP 110. Yang et al. demonstrated that ZnPT could induce TNBC cell death by disrupting the homeostasis of copper metabolism as well as triggering DLAT aggregation 111. Moreover, ZnPT inhibited TNBC cell proliferation, motility, stemness, and sensitized TNBC to chemotherapeutic effects, and ultimately inhibited TNBC development by inhibiting EGFR-PI3K-AKT and activating the MAPK signaling pathway. Deng et al. also constructed a risk model based on 4 CRLs, including C9orf163, PHC2-AS1, AC087741.1, and AL109824.1 after multiple analyses, and utilized this model to innovatively propose that the Hsp90 inhibitor 17-AAG was a candidate with potential therapeutic effects in high-risk groups 64.

Nano-complex-based drug-carrying systems can fully utilize the advantages of targeting, multiple synergistic functions, and safety 112-114. The induction and enhancement of PCD through nanocomplexes, such as cuproptosis, can not only promote tumor cell death, but also promote the release of immunogenic substances, promote immune activation, and amplify the therapeutic effect of the tumor 115. Of late, researchers focus on combining this advanced delivery method with cuproptosis induction, and have developed a series of novel drugs for BC. Inducing or enhancing cuproptosis by introducing high concentrations of copper and other agents is a common form. For instance, Chang et al. designed a polydopamine nanostructure (PDA-DTC/Cu) loaded with high concentrations of copper ions, which could enhance copper uptake and inhibit the expression of ATP7A and ATP7B, thereby reducing copper export and increasing intracellular copper accumulation to promote cuproptosis 116.

Additionally, tumor-associated macrophages were also stimulated to repolarize, alleviating immunosuppression within the tumor microenvironment. Overall, PDA-DTC/Cu demonstrated excellent tumor inhibitory effects by inducing cuproptosis as the core mechanism. Du et al. developed a self-reinforced bimetallic Mito-Jammer by constructing a hyaluronic acid -modified metal-organic framework loaded with doxorubicin and calcium peroxide 117. In 4T1 cell and 4T1 tumor-bearing models, the dissociation of calcium peroxide into hydrogen peroxide and Ca2+ enhanced the Cu2+-mediated Fenton reaction. This led to increased ROS production and mitochondrial damage, thereby significantly enhancing the sensitivity of tumor cells to cuproptosis and inhibiting tumor metastasis. In another study, Xu et al. synthesized disulfonamide-dimethylpyrimidine-phenanthroline-metal complexe HA-Cu, which demonstrated superior inhibitory effects on TNBC both in vitro and in vivo 118. HA-Cu effectively suppressed tumor survival and progression through a synergistic mechanism involving antiproliferative, antiangiogenic, anti-inflammatory, pro-apoptotic, and cuproptosis-inducing effects. HA-Cu inhibited the VEGF/VEGFR2 signaling pathway and enhanced cuproptosis in MDA-MB-231 cells by downregulating FDX1 expression and upregulating HSP70 expression. He et al. fabricated a type of Cu-chelated cyanine dye to deliver copper ions in different oxidation states to 4T1 cells and 4T1 tumor-bearing mice to investigate their roles in combating TNBC 119. They found that Cu+, in comparison to Cu2+, exhibited improved antitumor performance by generating more hydroxyl radicals through a faster pathway that did not require glutathione reduction. Zhang et al. developed a BPTES-loaded biomimetic Cu-doped polypyrrole nanoparticle (CuP) nanosystem (PCB), utilising various components to actively target tumor sites, reduce GSH levels, and induce oxidative stress and cuproptosis 120. PCB effectively inhibited the growth of both primary and distal tumors. By introducing glucose oxidase (GOx) and Cu sulfate, Lee et al. constructed a HD/BER/GOx/Cu hydrogel system for converting accumulating glucose into hydroxyl radicals and starvation/chemodynamic therapy by introducing glucose oxidase (GOx) and copper sulfate 121. The system enabled a multitude of tumor-killing effects through sustained release of drugs, including, notably, cupping-induced chemotherapy. In another study, Ning et al. designed a nanodelivery platform based on multifaceted induction of cupping, consisting of platelet vesicle (PV)-coated cuprous oxide nanoparticles (Cu2O)/TBP-2 cupping sensitization system (PTC) 122. This PTC system was able to release copper ions intracellularly, inhibit copper efflux, and further lead to lipoyl protein aggregation and iron-sulfur protein depletion, resulting in proteotoxic stress and cuproptosis. In this mechanism, PTC ultimately inhibited BC lung metastasis and enhanced T-cell immune effects.

Some studies have attempted to combine inducing cuproptosis with other antitumor therapies to enhance therapeutic efficacy. For example, Li et al. designed a core-shell nanoparticle, CuP/Er, which was capable of co-delivering copper and Erastin to cancer cells, thereby synergistically inducing ferroptosis and cuproptosis 123. Furthermore, CuP/Er was found to promote T cell proliferation and infiltration, enhancing the efficacy of immune checkpoint blockade therapy, resulted in inhibited survival and metastasis of murine colorectal adenocarcinoma and TNBC. Huang et al. developed a poly (amidoamine) dendrimer modified with p-carboxybenzenesulfonamide, loaded with copper peroxide nanoparticles, and combined with iron (Fe)-tannic acid (TF) networks to create a nanocomposite (CuO2@G5-BS/TF) 124. This nanocomposite effectively targeted and was internalized by 4T1 cells for targeted MRI. Furthermore, CuO2@G5-BS/TF induced ferroptosis and cuproptosis in 4T1 cells by depleting GSH and overloading copper and iron, while also alleviating the acidity of the tumor microenvironment, thereby inhibiting tumor metastasis. This modality offerd an attractive new method for targeted MRI and treatment of TNBC (Figure 3).

The re-thinking of cuproptosis in BC

Researchers have long noted the association between copper and cancer 125,126. As an essential transition metal in the body, the dysregulation of copper metabolism can lead to a range of cellular metabolic dysfunctions. The normal function of copper ions in cancer cells depends on the interactions between various copper-related proteins. These include proteins involved in copper transmembrane transport such as CTR1, SLC25A3, ATP7A/B, proteins responsible for binding and storing copper ions like MT and glutathione, and copper chaperone proteins such as ATOX1, CCS, and COX17. The interaction of these proteins is fundamental in maintaining intracellular copper homeostasis 127-130. By engaging key molecules in these pathways, intracellular copper can directly participate in regulating multiple signaling pathways in tumor cells, including receptor tyrosine kinase (RTK)-related signaling pathways, phosphoinositide 3-kinase (PI3K)-AKT signaling pathway, mitogen-activated protein kinase (MAPK) signaling pathway, and Notch pathway 131-134. These pathways influence tumor metabolism, proliferation, angiogenesis, and metastasis.

Elevated copper levels have been found in the tumors and serum of various animal models and cancer patients, including prostate cancer, BC, thyroid cancer, lung cancer, and gastric cancer. In lung cancer patients, higher serum copper ion concentrations are associated with worse clinical staging in northeast china 135. Based on the major discovery that copper can induce cell death, cuproptosis is considered a promising direction for cancer therapy. By regulating copper levels in tumour cells, normal biochemical processes can be disrupted, thereby inhibiting the proliferation and survival of cancer cells. Consequently, the profound interconnection between cuproptosis and cancer represents a burgeoning area of interest. Tsvetkov et al. identified 10 genes significantly associated with the risk of cuproptosis through genome-wide knockout screening. Further analysis revealed that SLC31A1, ATP7A, and ATP7B were deeply involved in regulating intracellular copper homeostasis. These 13 genes were considered critical cuproptosis genes (CKGs) 28. Researchers have focused on the expression levels and clinical significance of these CKGs and some CRGs in different tumors. Interestingly, CKGs and CRGs seem to play different roles in various tumors. For instance, FDX1 encodes Ferredoxin1, which participates in multiple redox reactions and enhances the toxicity of copper ions by reducing them, playing a central role in cuproptosis 136,137. Elevated levels of FDX1 are observed in glioblastoma and female reproductive tumors, whereas its expression is downregulated in solid tumors like lung adenocarcinoma and hepatocellular carcinoma 138. High levels of FDX1 are associated with poor prognosis in patients with head and neck squamous cell carcinoma and low-grade glioma, but predict better prognosis in patients with cervical squamous cell carcinoma and clear cell renal cell carcinoma. Similar effects can be observed in another CKG, namely LIAS. The high expression of LIAS is associated with poor prognosis in lung cancer, whereas in KIRC and ovarian cancer, high expression of LIAS indicates better prognosis 139.

Given that research on cuproptosis is still in its early stages, further studies are needed to elucidate the reasons for these differential expressions in various tumors and the specific mechanisms by which these differences impact prognosis. On one hand, this may be because these CKGs are involved not only in cuproptosis-related pathways but also in regulating biological processes, such as immune infiltration, energy metabolism, and methylation. In pan-cancer analyses, these genes exhibit different characteristics in various tumors 140. On the other hand, it may also be related to the inherent characteristics of some tumors. For example, there is a significant correlation between cuproptosis and mitochondrial metabolic levels, and certain tumors inherently exhibit higher levels of mitochondrial metabolism, such as melanoma, BC, and leukemia 141,142. Therefore, inducing cuproptosis as a means to treat tumors is more likely to yield ideal therapeutic effects in these types of cancers.

BC exhibits significant heterogeneity, both among different patients and within tumors from the same individual, primarily characterized by variations in hormone receptor status, HER2 expression, mutational landscape, and intratumoral heterogeneity 143,144. Hormone receptor-positive (ER+ and/or PR+) and TNBC differ markedly in their biological characteristics, treatment responses, and prognoses 145,146. HER2-positive tumors are particularly responsive to HER2-targeted therapies like trastuzumab but may exhibit reduced sensitivity to other treatments 147. Common genetic mutations in BC include TP53, PIK3CA, and GATA3, which influence the malignancy and therapeutic responses of the tumors 148,149. Additionally, intra-tumor heterogeneity is evident, with different cellular subpopulations within a single breast tumor displaying variations in cell morphology, proliferative capacity, and gene expression patterns 150. This extensive molecular heterogeneity not only dictates the biological behaviors of BC but also directly impacts its response to various therapeutic strategies.

BC cells exhibit a unique copper metabolism, requiring higher amounts of copper, which makes them more sensitive to cuproptosis inducers. Research indicates that dysregulation in copper metabolism is closely related to malignant progression of BC. High expression of copper transport proteins, such as SLC31A1, facilitates copper uptake, leading to the occurrence of cuproptosis 151. Dysregulation of copper metabolism-related genes affects copper homeostasis, causing intracellular copper ion accumulation and triggering cuproptosis. By regulating the expression of these genes, the growth and proliferation of BC cells can be effectively controlled. For instance, TNBC shows a high copper demand and sensitivity to cuproptosis inducers like ZnPT 111. This disrupts copper metabolic homeostasis and induces cell death by DLAT aggregation, thereby inhibiting proliferation, migration, and stemness. The unique relationship between cuproptosis and BC highlights the role of molecular heterogeneity in determining therapeutic responses. Different BC subtypes exhibit distinct responses to cuproptosis-inducing therapies 152. Hormone receptor-positive BC cells are sensitive to hormone therapy but may respond weakly to cuproptosis inducers; however, this can be improved through combination treatments. HER2-positive BC cells, while responsive to HER2-targeted therapies like trastuzumab, require further investigation to understand their response to cuproptosis inducers. Combining HER2-targeted therapies with cuproptosis inducers could be an effective strategy, as copper metabolism may interact with the HER2 signaling pathway, influencing cell growth and proliferation. TNBC, with its high dependency on copper metabolism, presents significant potential for the application of cuproptosis inducers, offering a promising approach for its treatment.

Discussion

In this study, we systematically elucidated the cuproptosis mechanism, the regulatory mechanism of cuproptosis on BC, the application of cuproptosis in the diagnosis and prediction of BC, and the therapeutic strategy of BC based on cuproptosis. However, there are some limitations and outlooks that need close attention in the current field.

First, cuproptosis has been poorly studied in BC in general, and most of these studies are still in the data mining related to cuproptosis. The biological processes of BC involve many different types of PCD modalities, including apoptosis, ferroptosis, autophagy, and cuproptosis 153,154. Compared to other forms of PCD, experiments related to cell, animal, and drug mining for cuproptosis are less reported. This implies that the roles and mechanisms of cuproptosis-related molecules in BC that have been mined so far are still full of mysteries. Different PCD patterns are co-existed in the BC progression, as evidenced by that simultaneous inductions of cuproptosis and ferroptosis in BC cells inhibit BC cell malignant behaviors 124. Furthermore, BC is a highly heterogeneous solid tissue with a complex composition, which also encompasses complex pathological and molecular typing. The responsiveness of different BC subtypes to cuproptosis is significantly different. Previous studies of cuproptosis often did not give a clear qualification of the subtypes in BC, and only in a few studies did they indicate the subtypes as TNBC or ER+ BC. The possibility that different subtypes may differ in their responsiveness to cuproptosis is a subsequent point that needs to be addressed urgently. It is also important to note that most of the cuproptosis focuses on the tumor cells themselves in the TME, while the cuproptosis effects of other stromal and immune cells have been reported. Overall, cuproptosis, as an emerging research hotspot, still lacks a large number of high-quality basic studies to confirm its role and mechanism in BC.

Cuproptosis has shown significant potential in the diagnosis of BC. In BC diagnostics, CRGs and CRLs provided valuable key information, such as rich tumor immunoprediction and clinical prediction. Risk models constructed from different CRGs have been widely recognized. BC is a heterogeneous entity composed of a variety of immune cells, stromal cells, and tumor cells 155,156. CRG-related model is not only capable of determining the prognosis, but also analyzing the characteristics of the cellular components of the entity microenvironment, the intensity of immunity, the TMB, and the assessment of the responsiveness to treatment. These provide rational therapeutic windows and strategies for precise therapies of BC. Risk models constructed based on multiple CRGs or combining CRGs and other ncRNAs together demonstrated excellent predictive capabilities. However, cuproptosis-based markers are still in the very early stages of validation. Nost of the studies are still at the stage of basic research and data mining, lacking large-scale clinical validation. In addition, the clinical translation of CRG models faces challenges, including the need for standardized detection methods and large-scale clinical trials. More in-depth retrospective and prospective studies are necessary to establish cuproptosis as a useful adjunct to traditional diagnostic methods in clinical practice.

Finally, in tumor therapy, the antitumor potential and safety of a large number of copper chelators and copper complexes have been preliminarily demonstrated in preclinical cell and animal studies. Copper-related drugs represented by DSF and TTM can produce synergistic therapeutic effects with other chemotherapeutic agents, inhibiting tumor resistance, suppressing tumor recurrence as well as sensitizing drug effects 157,158. However, compared with copper homeostasis-related genetic diseases, the application of cuproptosis-targeted therapy for tumors is not well established. In BC, the relevant therapeutic applications are in the cellular and animal studies of cuproptosis induction, and the specific mechanisms and applicable individuals have not been fully analyzed. Moreover, the number of these studies is relatively small, and continued exploration is necessary for the treatment of BC. In addition, since curpoptosis is a novel PCD mechanism that has been relatively little and superficially studied in BC, the modulation of tumor immunity has not been given a clear exploration. However, PCD produces damage-associated molecular patterns that contribute to antitumor immunotherapy, stimulate inflammatory responses, and mediate the activation of a variety of immune cells and factors, making the induction of PCD a potential immunotherapeutic strategy 159,160. Moreover. These types of cell death are not independent, but are closely cascaded or coordinated, and the use of nanomedicines can induce a combination of PCDs for treatment.

Finally, the increased copper requirement of tumour cells may be related to the role of copper in cell proliferation and metabolic activities. However, excess copper confers an anti-tumour effect by inducing copper toxicity, which is toxic to cancer cells. Copper is also an ion essential for normal physiological cellular activity, and the concentration must be maintained within a specific physiological range. To achieve therapeutic copper overload while minimizing damage to normal tissues, precise control over copper delivery and concentration is crucial. Additionally, targeted delivery systems or selective activation mechanisms could help specifically induce cuproptosis within the tumor microenvironment, thereby reducing adverse effects on normal cells.

Conclusion

Collectively, the delicate equilibrium of copper ions within the human body is essential for maintaining cellular homeostasis and is intricately linked to the pathogenesis and progression of BC. Cuproptosis has gradually emerged to play an increasingly prominent role in BC, including influencing the proliferation, invasion, prognosis, and treatment of BC. CRGs and CRLs based on cuproptosis have also demonstrated rich predictive information for BC. In addition, therapeutic strategies targeting cuproptosis are capable of capabilities to elicit positive therapeutic effects. Compared with other PCD types, cuproptosis currently has a long way to go in BC, which will provide a theoretical basis for cuproptosis-targeted therapy. Lasly, cuproptosis sheds light on the copper dependency and metabolic characteristics of BC, providing new avenues for precision medicine and personalized therapeutic strategies.

Funding

This work was financially supported by Natural Science Foundation of Hubei Province (2022CFB298), Shenzhen Nanshan District Health Bureau (NSZD2024042), and Wuhan University Education and Development Foundation (No. 2002330).

Author contributions

ZZ and KZ performed the literature search and prepared the original draft. YZ, QZ and JZ conceived the project, reviewed and revised the manuscript. All authors participated in the manuscript and approved the final version.

Consent for publication

All the authors agreed to be published.

Abbreviations

ATOX1 copper molecular chaperone antioxidant 1

ATP7A ATPase copper transporting alpha

ATP7B ATPase copper transporting beta

BC breast cancer

CAFs cancer-associated fibroblasts

CCO cytochrome oxidase C

CDI cell death index

CDKN2A cyclin-dependent kinase inhibitor 2A

CIC cancer immunity cycle

CKGs critical cuproptosis genes

CRGs cuproptosis-related genes

CRLs cuproptosis-related lncRNAs

CTR1 copper transport protein 1

DLAT dihydrolipoamide S-acetyltransferase

DLD dihydrolipoyl dehydrogenase

DMFS distant metastasis-free survival

ER+ estrogen receptor-positive

GOx glucose oxidase

ICIs immune checkpoint inhibitors

MAPK mitogen-activated protein kinase

OS overall survival

PV platelet vesicle

PCDs programmed cell deaths

PDHA1 pyruvate dehydrogenase E1 component subunit alpha

PI3K phosphoinositide 3-kinase

ROS reactive oxygen species

RFS recurrence-free survival

RTK receptor tyrosine kinase

SCFA short-chain fatty acid

STEAP six-transmembrane epithelial antigen of the prostate

SLC31A1 solute carrier family 31 member 1

SOD1 superoxide dismutase 1

TCA tricarboxylic acid

TLR4 Toll-like receptor 4

TME tumor microenvironment

TMB tumor mutation burden

TNBC triple negative breast cancer

ZnPT zinc pyrithione

Figure 1 Mechanisms of cuproptosis. Extracellular copper exists primarily in the form of Cu2+, which can directly enter the cell via DMT1 or travel through CTR1 after being reduced to Cu+ by STEAP. Cu+ enters the cell and binds to different copper ion carriers, thus avoiding its cytotoxicity, and there are four main destinations: 1) Binds to GSH or MT1/2 to be stored, forming an unstable copper pool; 2) Binds to CCS, then translocates to and inserts into SOD1, which participates in the detoxification of ROS; 3) Binds to ATOX1 and is targeted for translocation to ATP7A/B in the trans-Golgi network, contributing to copper enzyme synthesis or copper efflux; 4) Binds to COX17 and targets for transporting to the mitochondrial membrane interstitials, inserting into CCO and engaging in the cytosolic oxidative respiratory chain. The classical mechanism of cuproptosis primarily involves the aggregation of lipoylated TCA cycle proteins and the loss of Fe-S clusters in the mitochondria. FDX1 and LIAS regulate the lipoylation of mitochondrial proteins. High intracellular concentrations of Cu+ can bind to lipoylated proteins and foster their aggregation. Cu+ can also destabilize the Fe-S Cluster, leading to a reduction in the Fe-S Cluster. These can lead to Cu-induced proteotoxic stress and ultimately cell death.

Figure 2 Cuproptosis-related functions in BC progression. Some CRGs are involved in the development and progression of BC. Inhibition of CDKN2A downregulates the expression of a series of proteins associated with tumor proliferation and migration, leading to a better prognosis of BC. LncRNA-C6orf99 can enhance the expression of DLD by regulating the expression of hsa-miR-370-3p and hsa-miR-432-5p, thus strengthening the tolerance of BC cells to endocrine therapy. LINC00511 and LINC01614 could act on miR-29-3p and miR-204-5p, respectively, to enhance the expression of SLC31A1, which was associated with worse prognosis of BC. Increased c-Myc expression may also promote BC progression through cuproptosis. LncRNA-XIST can inhibit BC progression by targeting the miR-92b-3p/MTF1 axis. LncRNA-CARMN can promote PRNP expression by regulating hsa-miR-192-5p and hsa-miR-215-5p, thereby inhibiting the development of BC. Butyrate promotes the expression of PDXK and SLC25A28 by inhibiting TLR4, thereby promoting cuproptosis in tumour cells.

Figure 3 Therapy targeting cuproptosis in BC. Researchers have developed some drugs that can inhibit the development of BC by modulating cuproptosis in BC cells. These drugs, mostly in nano form, can induce cuproptosis in BC cells in a variety of ways or combine the induction of cuproptosis with other therapeutic approaches, yielding promising results in the treatment of BC.

Table 1 Cuproptosis-related applications in Breast Cancer diagnosis.

Related Molecule	Diagnosis application	Reference	
SLC31A1	Integrated SLC31A1 with other clinical parameters, such as age, T-stage, N-stage, and clinical staging.	Ref.17	
PDHA1	PDHA1 was a regulator of BC malignant progression and its expression was tightly correlated with the infiltration of a variety of immune cells.	Ref.81	
DLAT, SLC31A2, SLC25A3, ATOX1	Classifying HER2+ BC patients into low-risk and high-risk groups by risk scores, effectively assess the prognosis of HER2+ BC patients.	Ref.53	
CASC 8, LINC 02188, LINC 00511, GRIK 1-AS 1, ROCR	The AUC of the model constructed for the prediction of breast cancer subtypes was 0.816 and the F1 score was 0.57. In addition, the precision of the model was 0.56, the specificity was 0.81, and the sensitivity (Sn) was 0.61.	Ref.84	
PTPRN2, SCARB1, SLC37A2, YES1, LY6D, and NOTCH3	With a high AUC score over 0.85 in TCGA dataset, high- and low-risk groups distinguished by the model had distinct prognosis and immune infiltration.	Ref.85	
TFF1, GREB1, SCUBE2, MMP7, SUSD3, CHI3L1, STC2, SLC7A5, MAPT, FABP7 and CHAD	Significant differences existed between the high- and low-risk groups in terms of OS, immune status, and sensitivity to chemotherapy.	Ref.86	
DKN2A、MTF1、PDHA1、DLD、LIPT1 and FDX1	The model predicted the OS rate with an accuracy that ranged from medium to high.	Ref.62	
FDX1, LIAS, LIPT1, DLD, PDHB, ATP7B and CDKN2A	The model specified a higher risk of recurrence with a high CRG score.	Ref.89	
PPIC-AS1, MME-AS1, AC012676.3, MFF-DT, OTUD6B-AS1, AL109936.9, AL807757.2, AL118556.1, AL137847.1	The predictive model classified patients into high-risk and low-risk groups, with a significantly higher mortality rate in the high-risk group. The results of the C-index curves indicated that the predictive model possesses a higher degree of accuracy in assessing prognosis than the clinicopathological features.	Ref.93	
AC104211.1, AL162595.1, LINC02166, AC007996.1, AC005865.2, AC007493.1, AL449423.1, AC004847.1, AL161910.1, LINC01863, AC018978.1, AC092384.3, AL356740.2	The model grouped patients according to thier scores, and the AUC values of the risk scores for predicting 1-, 3-, and 5-year survival of BC in the validation set were 0.73, 0.68, and 0.71, respectively.	Ref.94	
USP2-AS1, NIFK-AS1	BCCuS-high group and BCCuS-low group showed significant differences in gene mutation frequency, immune function, TIDE (tumor immune dysfunction and exclusion) score and other phenotypes.	Ref.95	
C2orf91(LINC02898), PRKAR1B-AS1, AC012213.3, AL137847.1, MFF-DT	These CRLs were closely related to immune responsiveness, the OS of patients in the high-risk group was lower than that in the low-risk group.	Ref.96	
AL139241.1、MFF-DT、AL451123.1、AC009120.5、AL137847.1、HECW 2-AS 1、LINC 01031、NIFK-AS 1、AL592301.1、U73166.1	The model categorized patients into high- and low-risk groups, the risk score was significantly relevant to the survival of BRCA patients and demonstrated a better predictive ability for 1- and 3-year survival with the AUC of approximately 0.74, as well as the potential of predicting immunotherapy responsiveness	Ref.97	
AL023882.1, AC091588.1, AC138028.2, AC027514.1, AL592301.1, LRRC8C-DT, MFF-DT, NIFK-AS1, MECOM-AS1, OTUD6B-AS1 and RNF32-AS1	Patients in the high-risk group distinguished by this model face heavier tumor mutational load (TMB), have suppressed anti-tumor immunity, and possess a worse prognosis.	Ref.98	
LRRC8C-DT, TDRKH-AS1, SAMMSON, SIAH2-AS1, WDFY3-AS2, LINC00393, ARHGAP28-AS1, PCAT18, and LINC01711	Patients with BC in the low-risk groups showed better clinical outcomes different immune cell infiltrations, with better response to immunotherapies.	Ref.99	
GORAB-AS1, AC 079922.2, AL 589765.4, AC 005696.4, Cytor, ZNF 197-AS1, AC 002398.1, AL 451085.3, YTH DF 3-AS1, AC 008771.1, LINC 02446	The model showed the ability to independently predict the prognosis and TMB, with the AUC values for ROC of 1-, 3-, and 5-year risk were 0.849, 0.779, and 0.794, respectively.	Ref.100	
AL118556.1, AL451123.1, MFF-DT, AL133243.2, ZKSCAN7-AS1, AC012676.3, AC009506.1, AC079766.1, MIR1915HG, AC138028.2	ROC and PCA showed that the model has accurate prediction ability, with higher tumor mutation burden and high TMB-resulted lower survival in high-risk group.	Ref.101	
ANO6, CHAC1, CHMP6, CS, EMC2, G6PD, GPX4, PANX1, PIK3CA, SLC7A5, and SOCS1	The model demonstrated differences in steroid biosynthesis, ABC transporters, and drug sensitivity to AKT inhibitor VIII and cisplatin between subgroups.	Ref.102	
miR-203a-3p, miR-1277-3p, miR-135b-5p, miR-200c-3p, miR-592, DENND5B, IGF1R, MEF2C	Patients were categorised into high- and low-risk groups based on risk scores from the model, which combined the cancer status and pathological staging to predict 1/3/5-year patient survival and provide new therapeutic targets for BC.	Ref.103	
CXCL13, HSPA2, HSPA9, MICB	A nomogram model was developed to predict survival in BC patients by linking risk scores to clinicopathological features and revealed that targeting HSPA9 could be a potential means of improving breast cancer outcomes.	Ref.104
==== Refs
1 Burstein HJ Curigliano G Thürlimann B Weber WP Poortmans P Regan MM Senn HJ Winer EP Gnant M Aebi S Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021 Annals of Oncology 2021 32 1216 1235 34242744
2 Ye F Dewanjee S Li Y Jha NK Chen Z-S Kumar A Vishakha Behl T Jha SK Tang H Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer Mol Cancer 2023 22 105 37415164
3 Li H Shi W Shen T Hui S Hou M Wei Z Qin S Bai Z Cao J Network pharmacology-based strategy for predicting therapy targets of Ecliptae Herba on breast cancer Medicine 2023 102 E35384 37832105
4 Xi G Guo W Kang D Ma J Fu F Qiu L Zheng L He J Fang N Chen J Large-scale tumor-associated collagen signatures identify high-risk breast cancer patients Theranostics 2021 11 3229 3243 33537084
5 Bertheloot D Latz E Franklin BS Necroptosis, pyroptosis and apoptosis: an intricate game of cell death Cell Mol Immunol 2021 18 1106 1121 33785842
6 Newton K Strasser A Kayagaki N Dixit VM Cell death Cell 2024 187 235 256 38242081
7 Christgen S Tweedell RE Kanneganti TD Programming inflammatory cell death for therapy Pharmacol Ther 2022 232 108010 34619283
8 Xu L Wang S Zhang D Wu Y Shan J Zhu H Wang C Wang Q Machine learning- and WGCNA-mediated double analysis based on genes associated with disulfidptosis, cuproptosis and ferroptosis for the construction and validation of the prognostic model for breast cancer J Cancer Res Clin Oncol 2023 149 16511 16523 37712959
9 Li M Wang ZW Fang LJ Cheng SQ Wang X Liu NF Programmed cell death in atherosclerosis and vascular calcification Cell Death Dis 2022 13 5 467 35585052
10 Hadian K Stockwell BR The therapeutic potential of targeting regulated non-apoptotic cell death Nat Rev Drug Discov 2023 22 723 742 37550363
11 Chen X Cai Q Liang R Zhang D Liu X Zhang M Xiong Y Xu M Liu Q Li P Copper homeostasis and copper-induced cell death in the pathogenesis of cardiovascular disease and therapeutic strategies Cell Death Dis 2023 14 2 105 36774340
12 De Luca A Barile A Arciello M Rossi L Copper homeostasis as target of both consolidated and innovative strategies of anti-tumor therapy J Trace Elem Med Biol 2019 55 204 213 31345360
13 Chen L Min J Wang F Copper homeostasis and cuproptosis in health and disease Signal Transduct Target Ther 2022 7 378 36414625
14 Kim JH Matsubara T Lee J Fenollar-Ferrer C Han K Kim D Jia S Chang CJ Yang H Nagano T Lysosomal SLC46A3 modulates hepatic cytosolic copper homeostasis Nat Commun 2021 12 1 290 33436590
15 Liu Y Wang J Jiang M Copper-related genes predict prognosis and characteristics of breast cancer Front Immunol 2023 14 1145080 37180167
16 Shen L He Y Fang C Qiu H Chen Q Huang F Wu Z Cuproptosis-associated genes and immune microenvironment characterization in breast cancer Medicine (United States) 2022 101 E32301
17 Li L Li L Sun Q High expression of cuproptosis-related SLC31A1 gene in relation to unfavorable outcome and deregulated immune cell infiltration in breast cancer: an analysis based on public databases BMC Bioinformatics 2022 23 350 35996075
18 Zou Y Xie J Zheng S Liu W Tang Y Tian W Deng X Wu L Zhang Y Wong CW Leveraging diverse cell-death patterns to predict the prognosis and drug sensitivity of triple-negative breast cancer patients after surgery International Journal of Surgery 2022 107 106936 36341760
19 Festa RA Thiele DJ Copper: An essential metal in biology Current Biology 2011 21 R877 R883 22075424
20 Jin X Liu W Miao J Tai Z Li L Guan P Liu J Copper ions impair zebrafish skeletal myofibrillogenesis via epigenetic regulation The FASEB Journal 2021 35 e21686 34101239
21 Cholewińska E Marzec A Sołek P Fotschki B Listos P Ognik K Juśkiewicz J The Effect of Copper Nanoparticles and a Different Source of Dietary Fibre in the Diet on the Integrity of the Small Intestine in the Rat Nutrients 2023 15 7 1588 37049430
22 Ohgami RS Campagna DR McDonald A Fleming MD The Steap proteins are metalloreductases Blood 2006 108 1388 1394 16609065
23 Pezacki AT Matier CD Gu X Kummelstedt E Bond SE Torrente L Jordan-Sciutto KL DeNicola GM Su TA Brady DC Oxidation state-specific fluorescent copper sensors reveal oncogene-driven redox changes that regulate labile copper(II) pools Proceedings of the National Academy of Sciences 2022 119 e2202736119
24 Lönnerdal B Intestinal regulation of copper homeostasis: a developmental perspective Am J Clin Nutr 2008 88 846S 850S 18779306
25 Ramos D Mar D Ishida M Vargas R Gaite M Montgomery A Linder MC Mechanism of Copper Uptake from Blood Plasma Ceruloplasmin by Mammalian Cells PLoS One 2016 11 e0149516 26934375
26 Moriya M Ho YH Grana A Nguyen L Alvarez A Jamil R Ackland ML Michalczyk A Hamer P Ramos D Copper is taken up efficiently from albumin and alpha2-macroglobulin by cultured human cells by more than one mechanism Am J Physiol Cell Physiol 2008 295 3 C708 21 18579803
27 Lutsenko S Dynamic and cell-specific transport networks for intracellular copper ions J Cell Sci 2021 134 jcs240523 34734631
28 Tsvetkov P Coy S Petrova B Dreishpoon M Verma A Abdusamad M Rossen J Joesch-Cohen L Humeidi R Spangler RD Copper induces cell death by targeting lipoylated TCA cycle proteins Science 2022 375 1254 1261 35298263
29 Chen L Li N Zhang M Sun M Bian J Yang B Li Z Wang J Li F Shi X APEX2-based Proximity Labeling of Atox1 Identifies CRIP2 as a Nuclear Copper-binding Protein that Regulates Autophagy Activation Angew Chem Int Ed Engl 2021 60 25346 25355 34550632
30 Fujieda N Umakoshi K Ochi Y Nishikawa Y Yanagisawa S Kubo M Kurisu G Itoh S Copper-Oxygen Dynamics in the Tyrosinase Mechanism Angew Chem Int Ed Engl 2020 59 13385 13390 32356371
31 Das A Ash D Fouda AY Sudhahar V Kim YM Hou Y Hudson FZ Stansfield BK Caldwell RB McMenamin M Cysteine oxidation of copper transporter CTR1 drives VEGFR2 signalling and angiogenesis Nat Cell Biol 2022 24 35 50 35027734
32 Xue Q Kang R Klionsky DJ Tang D Liu J Chen X Copper metabolism in cell death and autophagy Autophagy 2023 19 2175 2195 37055935
33 Sturtz LA Diekert K Jensen LT Lill R Culotta VC A Fraction of Yeast Cu,Zn-Superoxide Dismutase and Its Metallochaperone, CCS, Localize to the Intermembrane Space of Mitochondria Journal of Biological Chemistry 2001 276 38084 38089 11500508
34 Lutsenko S Barnes NL Bartee MY Dmitriev OY Function and regulation of human copper-transporting ATPases Physiol Rev 2007 87 1011 1046 17615395
35 Horn N Wittung-Stafshede P ATP7A-Regulated Enzyme Metalation and Trafficking in the Menkes Disease Puzzle Biomedicines 2021 9 4 391 33917579
36 Cobine PA Pierrel F Winge DR Copper trafficking to the mitochondrion and assembly of copper metalloenzymes Biochim Biophys Acta Mol Cell Res 2006 1763 759 772
37 Banci L Bertini I Ciofi-Baffoni S Hadjiloi T Martinelli M Palumaa P Mitochondrial copper(I) transfer from Cox17 to Sco1 is coupled to electron transfer Proc Natl Acad Sci U S A 2008 105 6803 6808 18458339
38 Bertini I Rosato A Menkes disease Cellular and Molecular Life Sciences 2008 65 89 91 17989919
39 McCauley SR Clark SD Quest BW Streeter RM Oxford EM Erratum: Review of canine dilated cardiomyopathy in the wake of diet-associated concerns J Anim Sci 2020 98 7 skaa209 32649741
40 Beinhardt S Leiss W Stättermayer AF Graziadei I Zoller H Stauber R Maieron A Datz C Steindl-Munda P Hofer H Long-term outcomes of patients with Wilson disease in a large Austrian cohort Clin Gastroenterol Hepatol 2014 12 683 689 24076416
41 Ge EJ Bush AI Casini A Cobine PA Cross JR DeNicola GM Dou QP Franz KJ Gohil VM Gupta S Connecting copper and cancer: from transition metal signalling to metalloplasia Nat Rev Cancer 2022 22 102 113 34764459
42 Guan D Zhao L Shi X Ma X Chen Z Copper in cancer: From pathogenesis to therapy Biomed Pharmacother 2023 163 114791 37105071
43 Xu Y Liu S Zeng L Ma H Zhang Y Yang H Liu Y Fang S Zhao J Xu Y An Enzyme-Engineered Nonporous Copper(I) Coordination Polymer Nanoplatform for Cuproptosis-Based Synergistic Cancer Therapy Advanced Materials 2022 34 e2204733 36054475
44 Michniewicz F Saletta F Rouaen JRC Hewavisenti R V Mercatelli D Cirillo G Giorgi FM Trahair T Ziegler D Vittorio O Copper: An Intracellular Achilles' Heel Allowing the Targeting of Epigenetics, Kinase Pathways, and Cell Metabolism in Cancer Therapeutics ChemMedChem 2021 16 2315 2329 33890721
45 Wang Y Zhang L Zhou F Cuproptosis: a new form of programmed cell death Cell Mol Immunol 2022 19 867 868 35459854
46 Cobine PA Brady DC Cuproptosis: Cellular and molecular mechanisms underlying copper-induced cell death Mol Cell 2022 82 1786 1787 35594843
47 Xiong C Ling H Hao Q Zhou X Cuproptosis: p53-regulated metabolic cell death? Cell Death Differ 2023 30 876 884 36755067
48 Xing X Cai W Shi H Wang Y Li M Jiao J Chen M The prognostic value of CDKN2A hypermethylation in colorectal cancer: A meta-analysis Br J Cancer 2013 108 2542 2548 23703248
49 Kreuger IZM Slieker RC van Groningen T van Doorn R Therapeutic Strategies for Targeting CDKN2A Loss in Melanoma J Invest Dermatol 2023 143 18 25.e1 36123181
50 Wan H Yang X Sang G Ruan Z Ling Z Zhang M Liu C Hu X Guo T He J CDKN2A was a cuproptosis-related gene in regulating chemotherapy resistance by the MAGE-A family in breast cancer: based on artificial intelligence (AI)-constructed pan-cancer risk model Aging 2023 15 11244 11267 37857018
51 Cheng T Wu Y Liu Z Yu Y Sun S Guo M Sun B Huang C CDKN2A-mediated molecular subtypes characterize the hallmarks of tumor microenvironment and guide precision medicine in triple-negative breast cancer Front Immunol 2022 13 970950 36052076
52 Wang R Xu K Chen Q Hu Q Zhang J Guan X Cuproptosis engages in c-Myc-mediated breast cancer stemness J Transl Med 2023 21 409 37353799
53 Sha R Dong X Yan S Dai H You L Guo Z Sun A Cuproptosis-related genes predict prognosis and trastuzumab therapeutic response in HER2-positive breast cancer Sci Rep 2024 14 1 2908 38316885
54 Xu L Yang L Zhang D Wu Y Shan J Zhu H Lian Z He G Wang C Wang Q Multi-omics analysis reveals the unique landscape of DLD in the breast cancer tumor microenvironment and its implications for immune-related prognosis Comput Struct Biotechnol J 2024 23 1201 1213 38545600
55 Zhang L Huang S Yuan Y Butyrate inhibits the malignant biological behaviors of breast cancer cells by facilitating cuproptosis-associated gene expression J Cancer Res Clin Oncol 2024 150 6 287 38833016
56 Yang S Wang X Zhou X Hou L Wu J Zhang W Li H Gao C Sun C ncRNA-mediated ceRNA regulatory network: Transcriptomic insights into breast cancer progression and treatment strategies Biomed Pharmacother 2023 162 114698 37060661
57 Zhu H Shi J Li W Bioinformatics analysis of ceRNA network of autophagy-related genes in pediatric asthma Medicine 2023 102 48 e36343 38050261
58 Dong N Li D Cai H Shi L Huang L Expression of lncRNA MIR193BHG in serum of preeclampsia patients and its clinical significance J Gynecol Obstet Hum Reprod 2022 51 5 102357 35301154
59 Braga EA Fridman M V Moscovtsev AA Filippova EA Dmitriev AA Kushlinskii NE LncRNAs in Ovarian Cancer Progression, Metastasis, and Main Pathways: ceRNA and Alternative Mechanisms Int J Mol Sci 2020 21 1 44
60 Kong Z Han Q Zhu B Wan L Feng E Circ_0069094 regulates malignant phenotype and paclitaxel resistance in breast cancer cells via targeting the miR-136-5p/YWHAZ axis Thorac Cancer 2023 14 1831 1842 37192740
61 Lian W Yang P Li L Chen D Wang C A ceRNA network-mediated over-expression of cuproptosis-related gene SLC31A1 correlates with poor prognosis and positive immune infiltration in breast cancer Front Med (Lausanne) 2023 10 1194046 37275369
62 Jiang B Zhu H Feng W Wan Z Qi X He R Xie L Li Y Database Mining Detected a Cuproptosis-Related Prognostic Signature and a Related Regulatory Axis in Breast Cancer Dis Markers 2022 2022 9004830 36312586
63 Wu J Cheng T Zhu B Gao H Zheng L Chen W Identification of cuproptosis-related gene SLC31A1 and upstream LncRNA-miRNA regulatory axis in breast cancer Sci Rep 2023 13 18390 37884650
64 Deng J Fu F Zhang F Xia Y Zhou Y Construct ceRNA Network and Risk Model of Breast Cancer Using Machine Learning Methods under the Mechanism of Cuproptosis Diagnostics 2023 13 1203 36980514
65 Zhang D Lu W Zhuo Z Wang Y Zhang W Zhang M Comprehensive analysis of a cuproptosis-related ceRNA network implicates a potential endocrine therapy resistance mechanism in ER-positive breast cancer BMC Med Genomics 2023 16 96 37143115
66 McDonald ES Clark AS Tchou J Zhang P Freedman GM Clinical Diagnosis and Management of Breast Cancer J Nucl Med 2016 57 Suppl 1 9S 16S 26834110
67 Kamal AM Sakorikar T Pal UM Pandya HJ Engineering Approaches for Breast Cancer Diagnosis: A Review IEEE Rev Biomed Eng 2023 16 687 705 35687618
68 Wang L Microwave Imaging and Sensing Techniques for Breast Cancer Detection Micromachines (Basel) 2023 14 1462 37512773
69 Yan S Wang W Zhu B Pan X Wu X Tao W Construction of Nomograms for Predicting Pathological Complete Response and Tumor Shrinkage Size in Breast Cancer Cancer Manag Res 2020 12 8313 8323 32982426
70 Li J Wu F Li C Sun S Feng C Wu H Chen X Wang W Zhang Y Liu M The cuproptosis-related signature predicts prognosis and indicates immune microenvironment in breast cancer Front Genet 2022 13 977322 36226193
71 Shi B Zhang W Wang T Cui Z The therapeutic and prognostic role of cuproptosis-related genes in triple negative breast cancer BMC Bioinformatics 2023 24 1 223 37259036
72 Li W Zhang X Chen Y Pang D Identification of cuproptosis-related patterns and construction of a scoring system for predicting prognosis, tumor microenvironment-infiltration characteristics, and immunotherapy efficacy in breast cancer Front Oncol 2022 12 966511 36212436
73 Li Z Zhang H Wang X Wang Q Xue J Shi Y Wang M Wang G Zhang J Identification of cuproptosis-related subtypes, characterization of tumor microenvironment infiltration, and development of a prognosis model in breast cancer Front Immunol 2022 13 996836 36059516
74 Sha S Si L Wu X Chen Y Xiong H Xu Y Liu W Mei H Wang T Li M Prognostic analysis of cuproptosis-related gene in triple-negative breast cancer Front Immunol 2022 13 922780 35979353
75 Chen H Li H Wang L Li Y Yang CY A 5-gene DNA methylation signature is a promising prognostic biomarker for early-stage cervical cancer J Obstet Gynaecol 2022 42 327 332 34082663
76 Dang X Xiong G Fan C He Y Sun G Wang S Liu Y Zhang L Bao Y Xu J Systematic external evaluation of four preoperative risk prediction models for severe postpartum hemorrhage in patients with placenta previa: A multicenter retrospective study J Gynecol Obstet Hum Reprod 2022 51 4 102333 35151929
77 Pan S Song C Meng H Li N Li D Hao B Lu Z Geng Q Identification of cuproptosis-related subtypes in lung adenocarcinoma and its potential significance Front Pharmacol 2022 13 934722 36263125
78 Mi J Luo J Zeng H Zhang H Jamil M Abdel-Maksoud MA Zakri AM Alfuraydi AA Zhang N Xiao M Elucidating cuproptosis-related gene SLC31A1 diagnostic and prognostic values in cancer Am J Transl Res 2023 15 6026 6041 37969191
79 An S Yao Y Hu H Wu J Li J Li L Wu J Sun M Deng Z Zhang Y PDHA1 hyperacetylation-mediated lactate overproduction promotes sepsis-induced acute kidney injury via Fis1 lactylation Cell Death Dis 2023 14 457 37479690
80 Deng L Jiang A Zeng H Peng X Song L Comprehensive analyses of PDHA1 that serves as a predictive biomarker for immunotherapy response in cancer Front Pharmacol 2022 13 947372 36003495
81 Huang T Liu Y Li J Shi B Shan Z Shi Z Yang Z Insights into prognosis and immune infiltration of cuproptosis-related genes in breast cancer Front Immunol 2022 13 350
82 Bao JH Lu WC Duan H Ye YQ Li JB Liao WT Li YC Sun YP Identification of a novel cuproptosis-related gene signature and integrative analyses in patients with lower-grade gliomas Front Immunol 2022 13 933973 36045691
83 Shen Y Li D Liang Q Yang M Pan Y Li H Cross-talk between cuproptosis and ferroptosis regulators defines the tumor microenvironment for the prediction of prognosis and therapies in lung adenocarcinoma Front Immunol 2023 13 1029092 36733399
84 Xia Q Shen J Wang Q Chen R Zheng X Yan Q Du L Li H Duan S Cuproptosis-associated ncRNAs predict breast cancer subtypes PLoS One 2024 19 2 e0299138 38408075
85 Zhu B Wang S Wang R Wang X Identification of molecular subtypes and a six-gene risk model related to cuproptosis for triple negative breast cancer Front Genet 2022 13 1022236 36386788
86 Zheng Q Shi S Zhang N Chen H A novel cuproptosis-related genes model in breast cancer prognosis Medicine 2023 102 e34507 37543823
87 Aouad P Zhang Y De Martino F Stibolt C Ali S Ambrosini G Mani SA Maggs K Quinn HM Sflomos G Epithelial-mesenchymal plasticity determines estrogen receptor positive breast cancer dormancy and epithelial reconversion drives recurrence Nat Commun 2022 13 1 4975 36008376
88 Hanker AB Sudhan DR Arteaga CL Overcoming Endocrine Resistance in Breast Cancer Cancer Cell 2020 37 496 513 32289273
89 Fan Y Luo C Wang Y Wang Z Wang C Zhong X Hu K Wang Y Lu D Zheng H A nomogram based on cuproptosis-related genes predicts 7-year relapse-free survival in patients with estrogen receptor-positive early breast cancer Front Oncol 2023 13 1111480 37251943
90 Ding D Wang L Zhang Y Shi K Shen Y Machine learning developed a programmed cell death signature for predicting prognosis and immunotherapy benefits in lung adenocarcinoma Transl Oncol 2023 38 101784 37722290
91 Chen L Yang H Li H He C Yang L Lv G Insights into modifiable risk factors of cholelithiasis: A Mendelian randomization study Hepatology 2022 75 785 796 34624136
92 Wu X Zhang Y Liang G Ye H Cuproptosis-related lncRNAs potentially predict prognosis and therapy sensitivity of breast cancer Front Pharmacol 2023 14 1199883 37529698
93 Li F Yang Y Zhang X Yu J Yu Y A novel prognostic model of breast cancer based on cuproptosis-related lncRNAs Discover oncology 2024 15 1 35 38353835
94 Sun L Chen X Li F Liu S Construction and significance of a breast cancer prognostic model based on cuproptosis-related genotyping and lncRNAs J Formos Med Assoc 2024 20 S0929 6646 (24)00243-2
95 Xu QT Wang ZW Cai MY Wei JF Ding Q A novel cuproptosis-related prognostic 2-lncRNAs signature in breast cancer Front Pharmacol 2023 13 1115608 36699089
96 Li C Zhang Y Construction and validation of a cuproptosis-related five-lncRNA signature for predicting prognosis, immune response and drug sensitivity in breast cancer BMC Med Genomics 2023 16 158 37422644
97 Li Y Na F Pei J Construction and characterization of a cuproptosis- and immune checkpoint-based LncRNAs signature for breast cancer risk stratification Breast Cancer 2023 30 393 411 36662399
98 Yu H Liu Y Zhang W Peng Z Yu X Jin F A signature of cuproptosis-related lncRNAs predicts prognosis and provides basis for future anti-tumor drug development in breast cancer Transl Cancer Res 2023 12 1392 1410 37434691
99 Guo Q Qiu P Pan K Lin J Comprehensive analysis of cuproptosis-related long non-coding RNA signature and personalized therapeutic strategy of breast cancer patients Front Oncol 2022 12 1081089 36620596
100 Jiang ZR Yang LH Jin LZ Yi LM Bing PP Zhou J Yang JS Identification of novel cuproptosis-related lncRNA signatures to predict the prognosis and immune microenvironment of breast cancer patients Front Oncol 2022 12 988680 36203428
101 Pan Y Zhang Q Zhang H Kong F Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer Funct Integr Genomics 2023 23 38 36640225
102 Zhang X Zhang Q A novel ferroptosis-related gene signature associated with cuproptosis for predicting overall survival in breast cancer patients Acta Biochim Pol 2023 70 875 884 37930188
103 Wang Y Wang J Jiang J Zhang W Sun L Ge Q Li C Li X Li X Shi S Identification of cuproptosis-related miRNAs in triple-negative breast cancer and analysis of the miRNA-mRNA regulatory network Heliyon 2024 10 7 e28242 38601669
104 Liu X Xu F Zhao K Liu Y Ye G Zhang X Qu Y Comprehending the cuproptosis and cancer-immunity cycle network: delving into the immune landscape and its predictive role in breast cancer immunotherapy responses and clinical endpoints Front Immunol 2024 15 1344023 38312844
105 Xie J Yang Y Gao Y He J Cuproptosis: mechanisms and links with cancers Mol Cancer 2023 22 46 36882769
106 Tong X Tang R Xiao M Xu J Wang W Zhang B Liu J Yu X Shi S Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research J Hematol Oncol 2022 15 174 36482419
107 Peng F Liao M Qin R Zhu S Peng C Fu L Chen Y Han B Regulated cell death (RCD) in cancer: key pathways and targeted therapies Signal Transduct Target Ther 2022 7 1 286 35963853
108 Wang W Mo W Hang Z Huang Y Yi H Sun Z Lei A Cuproptosis: Harnessing Transition Metal for Cancer Therapy ACS Nano 2023 17 19581 19599 37820312
109 Mangion SE Holmes AM Roberts MS Targeted Delivery of Zinc Pyrithione to Skin Epithelia Int J Mol Sci 2021 22 9730 34575891
110 Liu J Bai W Zhou T Xie Y Yang B Sun J Wang Y Li X Hou X Liu Z SDCBP promotes pancreatic cancer progression by preventing YAP1 from β-TrCP-mediated proteasomal degradation Gut 2023 72 1722 1737 36828627
111 Yang X Deng L Diao X Yang S Zou L Yang Q Li J Nie J Zhao L Jiao B Targeting cuproptosis by zinc pyrithione in triple-negative breast cancer iScience 2023 26 108218 37953954
112 Duan X Chan C Lin W Nanoparticle-Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy Angewandte Chemie - International Edition 2019 58 670 680 30016571
113 Ye L Yao Q Xu F He L Ding J Xiao R Ding L Luo B Preparation and antitumor activity of triphenylphosphine-based mitochondrial targeting polylactic acid nanoparticles loaded with 7-hydroxyl coumarin J Biomater Appl 2022 36 1064 1075 34338057
114 Zhang J Wang Y Bao C Liu T Li S Huang J Wan Y Li J Curcumin-loaded PEG-PDLLA nanoparticles for attenuating palmitate-induced oxidative stress and cardiomyocyte apoptosis through AMPK pathway Int J Mol Med 2019 44 672 682 31173176
115 Zhang Y Chen J Shi L Ma F Polymeric nanoparticle-based nanovaccines for cancer immunotherapy Mater Horiz 2022 10 361 392
116 Chang J Yin W Zhi H Chen S Sun J Zhao Y Huang L Xue L Zhang X Zhang T Copper Deposition in Polydopamine Nanostructure to Promote Cuproptosis by Catalytically Inhibiting Copper Exporters of Tumor Cells for Cancer Immunotherapy Small 2024 20 27 e2308565 38339770
117 Du C Guo X Qiu X Jiang W Wang X An H Wang J Luo Y Du Q Wang R Self-Reinforced Bimetallic Mito-Jammer for Ca2+ Overload-Mediated Cascade Mitochondrial Damage for Cancer Cuproptosis Sensitization Adv Sci (Weinh) 2024 11 15 e2306031 38342617
118 Xu BB Jin N Liu JC Liao AQ Lin HY Qin XY Arene-Arene Coupled Disulfamethazines (or Sulfadiazine)-Phenanthroline-Metal(II) Complexes were Synthesized by In Situ Reactions and Inhibited the Growth and Development of Triple-Negative Breast Cancer through the Synergistic Effect of Antiangiogenesis, Anti-Inflammation, Pro-Apoptosis, and Cuproptosis J Med Chem 2024 67 7088 7111 38634624
119 He T Tang Q Ren Q Liu Y He G Pan Y Wang Z Huang P Lin J Different Valence States of Copper Ion Delivery against Triple-Negative Breast Cancer ACS Nano 2024 18 7 5434 5445
120 Zhang N Ping W Rao K Zhang Z Huang R Zhu D Li G Ning S Biomimetic copper-doped polypyrrole nanoparticles induce glutamine metabolism inhibition to enhance breast cancer cuproptosis and immunotherapy J Control Release 2024 371 204 215 38810704
121 Lee SY Seo J Kim S Hwang C Jeong DI Park J Yang M Huh JW Cho H Cuproptosis-Inducible Chemotherapeutic/Cascade Catalytic Reactor System for Combating with Breast Cancer Small 2023 19 e2301402 37162448
122 Ning S Lyu M Zhu D Lam JWY Huang Q Zhang T Tang BZ Type-I AIE Photosensitizer Loaded Biomimetic System Boosting Cuproptosis to Inhibit Breast Cancer Metastasis and Rechallenge ACS Nano 2023 17 10206 10217 37183977
123 Li Y Liu J Chen Y Weichselbaum RR Lin W Nanoparticles Synergize Ferroptosis and Cuproptosis to Potentiate Cancer Immunotherapy Adv Sci (Weinh) 2024 11 23 e2310309 38477411
124 Huang H Guo H Liu J Ni C Xia L Cao X Xia J Shi X Guo R Dendrimer/metal-phenolic nanocomplexes encapsulating CuO2 for targeted magnetic resonance imaging and enhanced ferroptosis/cuproptosis/chemodynamic therapy by regulating the tumor microenvironment Acta Biomater 2024 15 183 252-263
125 Liu WQ Lin WR Yan L Xu WH Yang J Copper homeostasis and cuproptosis in cancer immunity and therapy Immunol Rev 2024 321 211 227 37715546
126 Blockhuys S Celauro E Hildesjö C Feizi A Stål O Fierro-González JC Wittung-Stafshede P Defining the human copper proteome and analysis of its expression variation in cancers Metallomics 2017 9 112 123 27942658
127 Yu Z Zhou R Zhao Y Pan Y Liang H Zhang JS Tai S Jin L Teng CB Blockage of SLC31A1-dependent copper absorption increases pancreatic cancer cell autophagy to resist cell death Cell Prolif 2019 52 2 e12568 30706544
128 van Rensburg MJ van Rooy M Bester MJ Serem JC Venter C Oberholzer HM Oxidative and haemostatic effects of copper, manganese and mercury, alone and in combination at physiologically relevant levels: An ex vivo study Hum Exp Toxicol 2019 38 419 433 30537864
129 Kim BE Nevitt T Thiele DJ Mechanisms for copper acquisition, distribution and regulation Nat Chem Biol 2008 4 176 185 18277979
130 Casareno RLB Waggoner D Gitlin JD The copper chaperone CCS directly interacts with copper/zinc superoxide dismutase J Biol Chem 1998 273 23625 23628 9726962
131 He F Chang C Liu B Li Z Li H Cai N Wang HH Copper (II) Ions Activate Ligand-Independent Receptor Tyrosine Kinase (RTK) Signaling Pathway Biomed Res Int 2019 2019 4158415 31218225
132 Ostrakhovitch EA Lordnejad MR Schliess F Sies H Klotz LO Copper ions strongly activate the phosphoinositide-3-kinase/Akt pathway independent of the generation of reactive oxygen species Arch Biochem Biophys 2002 397 232 239 11795876
133 Turski ML Brady DC Kim HJ Kim B-E Nose Y Counter CM Winge DR Thiele DJ A novel role for copper in Ras/mitogen-activated protein kinase signaling Mol Cell Biol 2012 32 1284 1295 22290441
134 Baldari S Di Rocco G Heffern MC Su TA Chang CJ Toietta G Effects of Copper Chelation on BRAFV600E Positive Colon Carcinoma Cells Cancers (Basel) 2019 11 1 17
135 Wang W Wang X Luo J Chen X Ma K He H Li W Cui J Serum Copper Level and the Copper-to-Zinc Ratio Could Be Useful in the Prediction of Lung Cancer and Its Prognosis: A Case-Control Study in Northeast China Nutr Cancer 2021 73 1908 1915 32896161
136 Sheftel AD Stehling O Pierik AJ Elsässer HP Mühlenhoff U Webert H Hobler A Hannemann F Bernhardt R Lill R Humans possess two mitochondrial ferredoxins, Fdx1 and Fdx2, with distinct roles in steroidogenesis, heme, and Fe/S cluster biosynthesis Proc Natl Acad Sci U S A 2010 107 11775 11780 20547883
137 Tsvetkov P Detappe A Cai K Keys HR Brune Z Ying W Thiru P Reidy M Kugener G Rossen J Mitochondrial metabolism promotes adaptation to proteotoxic stress Nat Chem Biol 2019 15 681 31133756
138 Zhang C Zeng Y Guo X Shen H Zhang J Wang K Ji M Huang S Pan-cancer analyses confirmed the cuproptosis-related gene FDX1 as an immunotherapy predictor and prognostic biomarker Front Genet 2022 13 923737 35991547
139 Cai Y He Q Liu W Liang Q Peng B Li J Zhang W Kang F Hong Q Yan Y Comprehensive analysis of the potential cuproptosis-related biomarker LIAS that regulates prognosis and immunotherapy of pan-cancers Front Oncol 2022 12 952129 35982953
140 Liu H Pan-cancer profiles of the cuproptosis gene set Am J Cancer Res 2022 12 4074 36119826
141 Porporato PE Filigheddu N Pedro JMBS Kroemer G Galluzzi L Mitochondrial metabolism and cancer Cell Res 2018 28 265 280 29219147
142 Sriskanthadevan S Jeyaraju D V Chung TE Prabha S Xu W Skrtic M Jhas B Hurren R Gronda M Wang X AML cells have low spare reserve capacity in their respiratory chain that renders them susceptible to oxidative metabolic stress Blood 2015 125 2120 2130 25631767
143 Liu SQ Gao ZJ Wu J Zheng HM Li B Sun S Meng XY Wu Q Single-cell and spatially resolved analysis uncovers cell heterogeneity of breast cancer J Hematol Oncol 2022 15 1 19 35241110
144 Taylor BC Sun X Gonzalez-Ericsson PI Sanchez V Sanders ME Wescott EC Opalenik SR Hanna A Chou ST Van Kaer L NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer Cancer Discov 2024 14 290 307 37791898
145 Fan L Wang ZH Ma LX Wu SY Wu J Yu K Da Sui XY Xu Y Liu XY Chen L Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial Lancet Oncol 2024 25 184 197 38211606
146 Amgad M Hodge JM Elsebaie MAT Bodelon C Puvanesarajah S Gutman DA Siziopikou KP Goldstein JA Gaudet MM Teras LR A population-level digital histologic biomarker for enhanced prognosis of invasive breast cancer Nat Med 2024 30 85 97 38012314
147 Sirhan Z Thyagarajan A Sahu RP The efficacy of tucatinib-based therapeutic approaches for HER2-positive breast cancer Mil Med Res 2022 9 1 39 35820970
148 Martínez-Saéz O Chic N Pascual T Adamo B Vidal M González-Farré B Sanfeliu E Schettini F Conte B Brasó-Maristany F Frequency and spectrum of PIK3CA somatic mutations in breast cancer Breast Cancer Res 2020 22 1 45 32404150
149 Mosele F Stefanovska B Lusque A Tran Dien A Garberis I Droin N Le Tourneau C Sablin MP Lacroix L Enrico D Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer Ann Oncol 2020 31 377 386 32067679
150 Martelotto LG Ng CKY Piscuoglio S Weigelt B Reis-Filho JS Breast cancer intra-tumor heterogeneity Breast Cancer Res 2014 16 3 210 25928070
151 Wang J Li S Guo Y Zhao C Chen Y Ning W Yang J Zhang H Cuproptosis-related gene SLC31A1 expression correlates with the prognosis and tumor immune microenvironment in glioma Funct Integr Genomics 2023 23 3 279 37610668
152 Tang D Kroemer G Kang R Targeting cuproplasia and cuproptosis in cancer Nat Rev Clin Oncol 2024 21 370 388 38486054
153 Liang D Feng Y Zandkarimi F Wang H Zhang Z Kim J Cai Y Gu W Stockwell BR Jiang X Ferroptosis surveillance independent of GPX4 and differentially regulated by sex hormones Cell 2023 186 2748 2764.e22 37267948
154 Liao M Qin R Huang W Zhu HP Peng F Han B Liu B Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: a revisited perspective from molecular mechanisms to targeted therapies J Hematol Oncol 2022 15 1 44 35414025
155 Li J Li L Dong Y Zhong B Yin W Comprehensive Analysis of Cuproptosis Genes and Identification of Cuproptosis Subtypes in Breast Cancer Comb Chem High Throughput Screen 2023 26 1578 1593 36683372
156 Zhang Z Hu Y Chen Y Chen Z Zhu Y Chen M Xia J Sun Y Xu W Immunometabolism in the tumor microenvironment and its related research progress Front Oncol 2022 12 1024789 36387147
157 Wang X Zhou M Liu Y Si Z Cope with copper: From copper linked mechanisms to copper-based clinical cancer therapies Cancer Lett 2023 561 216157 37011869
158 Li N Sun Q Yu Z Gao X Pan W Wan X Tang B Nuclear-Targeted Photothermal Therapy Prevents Cancer Recurrence with Near-Infrared Triggered Copper Sulfide Nanoparticles ACS Nano 2018 12 5197 5206 29894162
159 Tang R Xu J Zhang B Liu J Liang C Hua J Meng Q Yu X Shi S Ferroptosis, necroptosis, and pyroptosis in anticancer immunity J Hematol Oncol 2020 13 1 110 32778143
160 Li J Liu J Zhou Z Wu R Chen X Yu C Stockwell B Kroemer G Kang R Tang D Tumor-specific GPX4 degradation enhances ferroptosis-initiated antitumor immune response in mouse models of pancreatic cancer Sci Transl Med 2023 15 720 eadg3049 37910602
